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Abstract
Using a murine model, we have previously showed that targeting an inactivated form of
F.tularensis (iFt) bacteria to Fc receptors by utilizing an IgG2a, anti-LPS monoclonal antibody
(mAb) provides 100% protection against a lethal dose with the live vaccine strain (LVS). The
binding of anti-LPS monoclonal antibodies and iFt create an immune complex (mAb-iFt)
allowing the Fc-region of the antibody to target Fc receptors expressed on antigen presenting
cells, leading to a more robust and effective processing and presentation of the bacterial antigens.
Although the resulting protective response generated relies on both humoral and cell-mediated
immunity, in our study we focus specifically on a subpopulation of T helper (TH) lymphocytes
by using C57BL/6 wild-type mice as an in vivo model for immunization and F. tularensis
infection. Mice were immunized using fixed bacteria (iFt) or immune complexes (mAb-iFt)
followed by a lethal dose of F. tularensis live vaccine strain (LVS) administered intranasal. Our
data suggests that Th17 cells (characterized as CD3+/CD4+/IL17A+/RORγT+ cells), a Tlymphocyte subpopulation involved in pathology during autoimmunity but also protection
against infectious diseases, was significantly increased in mAb-iFt immunized mice compared to
mice immunized with iFt alone. Furthermore, the increased levels of IL17A, a cytokine
predominantly secreted by Th17 cells, in the mAb-iFt immunized groups suggests a protective
role played by this T lymphocyte subpopulation in this F.tularensis vaccine model.
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1. Introduction
1.1 Immunity and Vaccination
There are two branches of the immune system constantly working together as a
defense against foreign pathogens. The innate immune system is considered the first line
of defense. It includes physical barriers such as mucous membranes, the skin, and cellular
components such as a system of complement proteins and phagocytes.
The adaptive immune system works in a more specific manner, and exhibits a
brief delay in activation at the expense of a more targeted response (Owen and Punt
2013). This adaptive branch primarily consists of cell-mediated and humoral components.
Should innate immune response not eliminate a pathogen, the adaptive immune system is
activated. This branch consists of natural killer cells, T lymphocytes, and B-lymphocytes
(responsible for antibody production). The adaptive immune system has high sensitivity
to small molecular differences between host self-antigens and pathogenic non-self
antigens.
Recognition of pathogens and foreign molecules is fundamental to the function of
the immune system. In innate immunity, this recognition occurs through patterns via
phagocytic cells such as macrophages, dendritic cells, and neutrophils. These immune
cells find molecular patterns known as PAMPs (pathogen associated molecular patterns).
A number of PAMPs can be recognized via receptors of the innate immune system,
notably molecular structures such as bacterial lipopolysaccharides (LPSs) on the surface
of gram-negative bacteria or viral double-stranded DNA. Foreign PAMP signals are
recognized by a variety of receptors known as PRRs (or pattern recognition receptors)
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expressed in a number of forms. For example, a class of transmembrane PRRs termed
toll-like receptors (TLRs) are responsible for the recognition of several PAMPs. LPS
molecular patterns are recognized via TLR4 and bacteria flagella are recognized via
TLR5. These associations set off a cascade of intracellular mechanisms resulting in the
induction of the adaptive immune response and release of pro-inflammatory proteins
(Owen and Punt 2013).
PRRs allow early categorization of which sort of pathogen the immune system is
dealing with, and are therefore powerful tools in the tailoring of a specific response to a
particular pathogen (Owen and Punt 2013). Once the innate immune cell receptors notice
PAMP signals, various cellular components are employed to engulf and process the
pathogen. The immune response becomes progressively more engaged as the pathogen
and its antigens are identified by host cells. Once identified, the adaptive immune branch
generally arrives with a primary response to an initial insult from a pathogen.
In large part, antibody activity defines the role of adaptive, humoral Blymphocyte immunity. This humoral B-lymphocyte response is employed for antibodies
to bind in a very specific manner to pathogens. The functional roles of antibodies can be
summarized into several categories. Agglutination is the clumping of foreign cells by
attachment of antibodies. Neutralization is the activity of antibodies to attach to the
surface of a target cell or even the secreted products of a pathogen to prevent attachment
to a host cell. Perhaps most relevant to this study is the use of antibodies as a beacon and
activator of other immune cells. Attachment of antibodies to foreign invaders marks them
for numerous cellular mechanisms including phagocytic uptake and complement
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activation. IgG is the most abundant form of antibody found within healthy individuals
constituting roughly 80% of all antibody production. Immunoglobulin G (IgG) antibodies
opsonize cells as targets for phagocytosis and activate the complement pathway.
(PubMed Health 2016). Recognition via this arm of the immune response comes in the
form of B-cell receptors on the surface of B-lymphocytes or in the solubilized form of
antibodies via Fab regions. The cell-mediated T-lymphocyte response does not have a
secreted form of receptor and relies on T-cell receptors for recognition. T-lymphocytes
have a multitude of roles; there exists cytotoxic, helper, and regulatory T cell groups.
Activation and recruitment of various immune cells and proteins summarize the activity
of helper T cells, while activated cytotoxic T cells produce perforin to directly destroy
pathogens or virally infected cells. Regulator T cells serve the role of suppressing the
immune response (PubMed Health 2016).
Generation of vast lymphocyte receptor diversity occurs during development and
maturation of T and B lymphocytes in primary and peripheral lymphoid organs (Owen
and Punt 2013). Specificity of target is key for the activation of the adaptive immune
response. Once the pathogen has been eliminated from the host system following primary
infection, these adaptive T cells and B cells will store a population of clonally selected
lymphocytes employed as defense (Santori 2015). This concept of immunological
memory allows for a quicker and more efficient response in the event of subsequent
infection. The deliberate exposure of a weakened or inactivated form of a pathogen
primes the immune system for a recall response to eliminate an otherwise more virulent
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and harmful form of similar pathogen. This intentional priming for a recall response is
the core concept of vaccination.
Because vaccination models use a form of the pathogen itself to elicit an immune
response, there is always a risk of infection becoming more widespread than intended.
Alternatively, if the pathogen’s virulence is significantly neutralized the immune system
may evoke the adaptive immune system to generate sufficient levels of memory cells. In
these instances, subsequent infection will remain harmful, as they are not eliminated
effectively. In order to maximize the generation of protective immune components
through vaccination, chemical or biological agents known as adjuvants are sometimes
employed in vaccine development in order to boost the immunogenicity of a particular
vaccine (Lee and Nguyen 2015).
1.2 Role of T lymphocytes in Immunity
Groups of cells that mature in the thymus, known as T cells, are generally
characterized by immunological roles and respective surface receptors. A large majority
of these thymic developing cells have alpha and beta glycoprotein chains on their surface,
therefore termed αβ T cells. In contrast, a minute number of γδ T cells have distinctive
gamma and delta glycoprotein surface chain receptors. Regardless, αβ T cells can be
divided into several effector subgroups (Owen and Punt 2013). αβ T cells will be the
topic of discussion throughout.
As previously mentioned, phagocytic cells are an essential component in the
clearance of foreign pathogens. Professional antigen presenting cells (APCs) play the role
of engulfing and digesting foreign invaders, ultimately leading to display of their
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constitutive peptide fragments via major histocompatibility complex proteins. The
cascade of intracellular events continues as antigens are recognized by T-cell receptors,
which activates that particular T cell. T cells are restricted in activation based on major
histocompatibility complex type I and II proteins (Rock et. al. 2016). The distinction of
MHC I proteins and MHC II proteins, in short, is that class I proteins derive antigens
from the cytoplasm while class II proteins present exogenous antigens that originate
extracellularly. They also vary based on the subset of mature T cell involved. T cells go
through two distinct selection processes during maturation. These rigorous processes of
positive and negative selection provide mature T cells with both MHC restriction and
self-tolerance (Owen and Punt 2013). One result is that cytotoxic CD8 T cells can only be
activated via MHC class I proteins, while CD4 T helper cells specifically recognize MHC
II presented antigens.
T cells have a clear division in roles amongst the subgroups of cytotoxic CD8 T cells and
helper CD4 T cells. Cytotoxic T cells eliminate tumor and infected host cells, favoring
endogenous MHC I presentation. Helper T cells guide the behavior of other immune
cells, fulfilling a critical role in many immune pathways. Through secretion of small
proteins known as cytokines, helper T cells activate and recruit other cell types such as B
cells, cytotoxic T cells, and innate immune cells such as macrophages. They also direct
the immune response away from responses that would otherwise favor certain pathogens.
Major subsets of helper T cells have also been established including Th1, Th2, Th17,
Treg, and TFH cells. There are polarizing cytokines, which induce the expression of each
subset of T helper cells. Each subset also has unique master gene regulators, or
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transcription factors. Likewise a set of effector cytokines, expressed following
differentiation, accompany each subset. There is also significant cross regulation of T
helper cells, notably in pairing Th1/Th2 subsets and Th17/Treg subsets, where the
upregulation of one leads to the downregulation of the other (Owen and Punt 2013).

1.3 Th17 Cells in Health and Disease
A specialized T helper cell subset known as Th17 (separate from Th1 and Th2)
cells has been identified as the primary source of IL-17 production. Much like IL-12 and
IL-4 are polarizing in for naïve CD4+ lymphocytes towards Th1 and Th2 lineages,
respectively, TGF-β is known to polarize naïve T helper cells towards the Th17 lineage in
the presence of IL-6 (Jin and Dong 2013). This distinction is further demonstrated in the
requirement for a novel set of transcription factors which show no overlap with the
transcription factors required for Th1 or Th2 cells, including signal transducer and
activator of transcription 3 (Stat3) and retinoic acid receptor related orphan receptor γ
(RORγ) (Jin and Dong 2013). Th17 cells reside mainly at mucosal sites such as in the
gastrointestinal tract and the airways. Although they were originally discovered as a
perpetrator of autoimmune disease, they are critical to mucosal homeostasis and
contribute to protection from bacterial and fungal pathogens (Stadhouders et al. 2017).
There is evidence of a protective role in vaccine induced long lived Th17 memory
cells. Lindenstrøm and colleagues (2012) explored the capacity of a cationic liposomeinduced adjuvant’s role in provoking a combined Th1 and Th17 response. They were able
to characterize a Th17 response two years post vaccination using a Mycobacterium
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tuberculosis challenge in this cationic adjuvant formulation (CAF) module. It was
demonstrated that a long-lived memory Th17 population is inducible. Furthermore, this
Th17 cell population maintained antigen specificity (Lindenstrøm et al. 2012). It is
proposed that a similar population is inducible following FcR-targeted intranasal
vaccination. These readily available cells having the immunological benefit of providing
tightly regulated pro-inflammation and polarizing a Th1-like response in a short period.
A mechanism the Francisella tularensis pathogen seems to utilize is the
suppression effect on Th1 responses observed in the presence of the cytokine IL-10
(Slight et al. 2013). IL-10 demonstrates a well-studied immunosuppressive capability. It
has also shown significant involvement in both the protection and pathogenicity of
Francisella tularensis infection. Th17 cells hold an interesting dynamic, as IL-10 is
found to be expressed in a subset of non-pathogenic Th17 cells to prevent overinflammation. In IL-10-/- mice, inflammation generated by IL-17 in pulmonary infected
mice leads to increased mortality following Francisella tularensis live vaccine strain
infection (Slight et al. 2013). This result indicates that IL-17 activity can mediate
protection via inflammation, but must be tightly regulated via anti-inflammatory
cytokines to avoid host pathology. It was further demonstrated that the role of IL-10
varies based on the route of infection of LVS. Interestingly, cutaneous LVS infection has
shown that knocking out IL-10 suppresses the potential pathogenic effects of IL-17,
while pulmonary LVS infection has shown a requirement of IL-10 to limit otherwise
harmful inflammation (Slight et al. 2013). Regardless of these findings, in hosts facing a
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SchuS4 challenge the presence of IL-10 appeared to play a less significant role in mouse
models as similar survival kinetics were observed (Metzger et al. 2013).
Th17 cells have also been shown to overcome the pathogens suppressive affect on
Th1 cells, specifically through the production of effector cytokine IFN-γ and production
of the polarizing cytokine IL-12. (Lin et al. 2009). To further explain the role of effector
cytokines released via Th17 cells, IL-17R-/- mouse models displayed inefficient clearing
of bacteria from lung, increased bacterial dissemination into the spleen, and a general
reduction in survival when faced with another gram-negative bacterium, Klebsiella
pneumonia (Curtis and Way 2009).
There is a seemingly unestablished middle ground of IL-17 activity. IL17A (the
predominant subtype of IL-17), has a primary role of mediating promotion of proinflammatory cytokines and chemokines, characterized by accumulation of neutrophils
and macrophages (Slight et al. 2013). A pathogenic effect of Th17 cells is also observed
in several major autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
The role of Th17 cells in MS has been shown using AEA models in mice to induce
central nervous system inflammation and lesion formation (Jin and Dong 2013). Further
studies of multiple sclerosis models have shown subsets of Th17 cells which contribute to
pathogenic and nonpathogenic effects. “Pathogenic” Th17 cells upregulate several
chemokine ligands, and do not express IL-10. “Nonpathogenic” Th17 cells, on the other
hand, produce IL-10. Nonetheless, these subsets still share the role of IL17A secretion
and polarization via TGF-β and IL-6 (Sharma et al. 2013).
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These subsets are dependent on the differentiation signals they receive. TGF-β1
plays a role in nonpathogenic Th17 cell polarization, while TGF-β3 plays a role in the
said pathogenic Th17 subset polarization (Sharma et al. 2013). The role of IL-23
dependency in the Th17 cell type is unclear. Some researchers have reported IL-23 to
induce switching of non-pathogenic Th17 cells to pathogenic (Lee 2013) while other
have found it to be required for expansion and maintenance (Stadhousers et. al. 2017).
IL-6 is another cytokine with a defined role in the Th17- Treg dynamic (Tanaka
et al. 2014). The IL-6 cytokine is considered pro-inflammatory and significant in the
polarization of naïve CD4 T cells to Th17 cells rather than Treg cells when TGF-β is also
present. In this way, IL-6 effective inhibits Treg differentiation. This dynamic is delicate
in the development of autoimmune and chronic inflammatory diseases (Tanaka et al.
2014).

1.4 F. tularensis Pathogenesis and Anti-Bacterial Immune Responses
Francisella tularensis is defined as a gram-negative intracellular bacterium,
capable of infecting humans through several routes of infection and causing tularemia.
Some common routes of infection include insect bites from infected organisms such as
horse and deer flies, and skin contact with infected animals. Most concerning to the
public, however, is inhalation of a contaminated aerosol (Celli and Zahrt 2013).
Transmission via this route of infection give F. tularensis organisms an unsettling
potential for use as a bio-weapon. This pneumonic route is the most potent route of
administration, leading F. tularensis infection to take on the name “lawnmower disease”.
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Mortality by pulmonary Francisella tularensis infection generally occurs via septic shock
and widespread inflammation (Sharma et al. 2011).
Several forms of the disease are commonly studied in the lab setting, including a
more virulent Type A SchuS4 strain developed from the tularensis subspecies. This strain
of the pathogen is known to cause infection with a dosage as low as roughly 10 colony
forming units, and an alarming mortality rate of roughly 60% if left untreated (Celli and
Zahrt 2013). Another subspecies of the disease, holarctica (Type B), displays milder
disease symptoms in humans. This subspecies has been used for the development of an
attenuated live vaccine strain (LVS), which retains its lethality in mice. The potential
weaponization of this bacterium, the lack of an approved vaccine, and the various routes
of infection has led the Center for Disease Control and Prevention to classify F.
tularensis as a category A bioterrorism threat (Celli and Zahrt 2013).
As many intracellular pathogens do, F. tularensis displays an ability to survive the
various mechanisms of phagocytes which generally cause pathogen death. Particularly,
this bacteria survives macrophage uptake and induction of toxic reactive oxygen species
(ROS) and reactive nitrogen species (RNS). The pathogen shows an ability to escape the
phagosome to replicate in the cytoplasm of the phagocyte, eventually leading to apoptosis
and escape from the cell. Analysis of the Francisella tularensis genome has revealed the
presence of several genes believed to be involved in the phagocytic survival and eventual
escape from phagocytes. For example, the gene encoding for IgLC. The IgLC protein has
demonstrated ability to inhibit phagosome maturation (Steiner et al. 2014). Another
protein coded by the “F. tularensis pathogenicity island” is the katG enzyme, which
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demonstrates an ability to detoxify hydrogen peroxide and reactive nitrogen species
(Steiner et al. 2014). This is evident in mice infected with a mutant strain lacking a
functional katG gene, which have shown survival to LVS challenge, but not the insult of
the SchuS4 strain (Steiner et al. 2014).
A characteristic of macrophages infected with F. tularensis is the expression of
prostaglandin E2 (PGE2) (Hunt et al. 2012). PGE2 is a great ally to many pathogens such
as Salmonella typhi, Mycobacterium tuberculosis, and Legionella pneumophila due to
immunosuppresion. In regards to F. tularensis, it has been shown that FT induced-PGE2
has the effect of directly acting on CD4 T helper cells to downregulate the production of
IFN-γ (Hunt et al. 2012). More indirectly, macrophages that produce FT induced-PGE2
also secrete a soluble factor (FTMØSN). This soluble factor has the effect of producing
IL-10 and through MARCH1 expression and an additional unknown intermediary step,
downregulate class II expression and induce ubiquitination on other macrophages. Lack
of MHC class II expression equates to less CD4 T cell activation. This result limits the
ability of cells to participate in an adaptive immune response (Hunt 2012).
Nonpathogenic Th17 cells also produce IL-10, so there must be a tolerable extent
produced in protected groups over the course of infection.
Research by Woolard and colleagues (2007) has established the role of these
PGE2 molecules to push the immune system towards a Th2-like response. This is a bad
thing for host defense. T helper type 1 responses are important for the production of proinflammatory cytokines, mainly IFN-γ, that are critical in immune response against
intracellular pathogens.
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The Th1 cytokine interferon-gamma (IFN-γ) has a known role in the immune
response directed towards limiting intracellular bacterial infection. Secretion of this
cytokine occurs primarily from the CD4+ Th1 cell population. In an IFN- γ dependent
manner, proliferation of the pathogen once it is inside the phagocyte and eventual
apoptosis of the cell (basis of the disease’s virulence) is hindered (Steiner et al. 2014).
Upregulation of Th1 cytokines, particularly IFN-γ, should therefore demonstrate the
effect of lessening F. tularensis pathogenicity.
In contrast to the effects of FT induced- PGE2; is the IL-17 cytokine, which is
primarily produced by Th17 cells. IL-17 has shown the ability to upregulate IL-12
production in both DCs and macrophages. Additionally IL-17 induces IFN-γ production
in macrophages and supports effective clearance of LVS. (Lin et al. 2009).
Defense against F. tularensis is multi-faceted. F. tularensis uptake by
macrophages occurs via looping phagocytosis after recognition by mannose receptors or
recognition by FcRs following opsonization (Steiner et al. 2014). This FcR uptake can be
used against F. tularensis in generating a primary response in a vaccine strategy. FcR
targeting of the pathogen to APCs has shown a pathway responsible for the generation of
F. tularensis-specific, gamma interferon (IFN-γ)-secreting, effector memory (EM) CD4+
T cells during infection. Furthermore, this pathway is shown to be adjuvant-independent
(Bitsaktsis et al. 2014).

16

1.5 Vaccination Models and FcγR-targeting
It is critical for vaccine models to remain immunogenic to generate pathogenspecific, long-lived memory lymphocytes. Vaccines should also not cause harmful side
effects to the host due to a heightened, often inflammatory, immune response. Various
vaccination strategies are available each having a unique set of benefits and potential
issues. For example, live, attenuated pathogens are regarded as one of the most effective
in eliciting an immune response, but at the cost of possible reversion back to virulence
while in the host. For example, multiple vaccination strategies have been employed
against poliomyelitis caused by the poliovirus. The Sabin oral polio vaccine (OPV)
contains a live, attenuated form of the virus. This OPV is favored for the poliomyelitis
eradication program due to its ability to induce a systematic and mucosal immune
response (Baicus 2012). Major risks arise using OPV vaccination in the appearance of
Vaccine-Associated Paralytic Poliomyelitis cases (VAPP) and the emergence of Vaccine
Derived Polioviruses strains. Reversion to neurovirulence can occur when the OPV
strains undergo genetic variation by point mutation during replication in the small
intestine. Such cases were reported during first dosage at a rate of 1 in 750,000 (Baicus
2012). Alternatively, the Salk formalin-inactivated polio vaccine (IPV) poses no risk of
vaccine related disease. This IPV strategy is used to phase out OPV use (Baicus 2012).
Manipulating pathogenic genomes via DNA vaccines is a field of study that has
been broadly expanded in recent years. Cloning a gene of interest into a plasmid vector
has shown promise in achieving an improved immune response in cellular studies (Lee et
al. 2012). Using this recombinant DNA approach, it is possible to target desired antigens
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to specific APCs (Lee et al. 2012). Inactivation or fixation of a pathogen is another
commonly used technique in vaccine development. A setback in this form of vaccination
is the low immunogenicity elicited in response, protection from live attenuated vaccines
typically outlasts that of a killed or inactivated vaccine (Lee et al. 2012). Adjuvants may
be employed to promote the immune response. However, the only vaccine adjuvant
approved for commercial usage is the use of aluminum salts, or Alum. These aluminum
salts are poor inducers of T cell responses (Lee and Nguyen 2015). Proper vaccine
development is tailored to obtain a desired type of antigen-specific immune response.
A novel approach to vaccine development is to utilize Fc-gamma receptors on
APCs to enhance the protective immune response. Various FcγRs are located on the
surface of APCs for antibody detection. FcγRs vary with proposed molecular
mechanisms that include both activating and inhibitory functions, along with distinct IgG
subclass binding affinities and cellular distribution. FcγRI is a receptor containing an
intracellular tyrosine activation molecule (ITAM). It is also a high affinity receptor
capable of binding monomeric and multimeric IgG (Poel et al. 2011). FcγRIIA and
FcγRIII are also receptors containing an ITAM. Both FcγRI and FcγRIII are
constitutively expressed on a number of cell types including APCs. Inversely, FcγRIIB
contains an intracellular tyrosine inhibitory molecule (ITAM) expressed on B cells.
While FcγRIIB inhibits B lymphocyte activation, it does not prevent it, and enhancement
of mucosal immunity is reported via FcγR targeting (Rawool et al. 2008). Using an
intranasal immunization model in mice which targets inactivated F. tularensis organisms
to Fcγ receptors via mouse IgG2a anti-LPS mAb has shown clear benefits. Improved
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uptake and presentation of iFt immunogen by APCs. Increased recruitment and activation
of dendritic cells in lungs. Enhanced F. tularensis-specific cytokine and antibody
response and generation of effector memory CD4 T cells are among the most notable of
these benefits. There is also a general increased protection against F. tularensis infection
(Babadjanova et al. 2015).
It was previously demonstrated that the FcR-targeted immunogen vaccination
method exhibits 100% protection against an otherwise lethal dosage of FT LVS challenge
(Iglesias et al. 2012). A goal of the current study is to further establish the usage of FcRtargeting as a viable option in vaccine development. It is proposed here that in secondary
immune tissues such as lung and spleen, there will be a clear cytokine profile of Th17
cells in protected groups. It is also expected that flow cytometry techniques will reveal
unique surface and intracellular markers of Th17 lymphocytes. Determining the presence
of surface markers of CD3 and CD4 will indicate the presence of T cells and T helper
cells, respectively. Confirming the intracellular presence of IL17A and the transcription
factor RORγT will give a unique characterization as Th17 cells. In addition, we aim to
see a distinctive cytokine profile of non-pathogenic Th17 cells. The anticipated cytokine
profile will show a TGF-β1 and IL-6 polarized cell population among protected groups.
Although the role of IL-23 is not entirely clear in pathogenic Th17 polarization, we
predict IL-23 to demonstrate expansion and maintenance of a protective T cell
subpopulation. It is proposed that immune tissue samples from protected groups will
show an increased presence of effector cytokines IL-6, IL-12, and IL-17A post-infection.
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In IC protected groups, significantly greater populations of Th17 cells are expected in
lung tissue samples during early stages of pulmonary infection.
Previous literature has demonstrated the effectiveness of the Fcγ-receptor
targeting vaccination strategy (Babadjanova et al. 2015). In the current study, further
investigation via ELISAs performed on tissue samples post immunization and challenge
showed distinct Th17 cytokine profiles. Tissue samples isolated from protected mice also
show evidence of positively identified Th17 cells in the early stages post infection. Flow
cytometry analysis gave qualitative and quantitative data for the presence of these cells
potentially being trafficked throughout the body of protected mice. The role of Th17 cells
in health and disease is not entirely clear. Our studies point towards a protective role of
Th17 cells over the course of bacterial infection.
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2. Materials & Methods:
2.1 Murine Model
C57BL/6 wild-type mice were purchased from Jackson Laboratories (Bar Harbor,
ME). These mice were housed and cared for in the rodent facilities in McNulty Hall,
Seton Hall University. The mice in which were utilized for experiments in this project
were 6-10 weeks of age. All protocols were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC).
2.2 F. tularensis Bacteria
The live vaccine strain of F. tularensis (FT LVS) was provided by Dr. Edmund
Gosselin (Albany Medical College, Albany, NY). The organisms were grown at 37oC to a
concentration of 2.6x109 CFU/mL, using Mueller-Hinton broth with a 2% IsovitaleXTM
(Fisher Scientific) supplement. Live F. tularensis samples were stored at -80oC in liquid
nitrogen.
2.3 Inactivation of Bacteria & Immune Complex Generation
Once FT LVS organisms were grown to a concentration of 2.6x109 CFU/mL in
Mueller-Hinton broth supplemented with 2% IsovitaleXTM (Fisher Scientific), 25 mL of
bacteria were centrifuged and resuspended in 25 mL of 2% paraformaldehyde and sterile
PBS solution for fixation. Samples were incubated at room temperature with shaking for
90 minutes. The inactivated bacteria were then centrifuged and washed three times with
sterile PBS. To confirm fixation, 100 uL of inactivated F. tularensis (iFt) at 2.6x108
CFU) were plated on nutrient rich chocolate blood agar plates for seven days. Aliquoted
samples were stored in PBS at -20oC. These inactivated samples were used as an
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immunogen for one vaccination protocol. These inactivated organisms were also used to
generate immune complexes (ICs) for a separate vaccination model in these experiments.
For generation of mAb-iFt immune complexes, 1x109 iFt bacterial organisms
were mixed with IgG2a anti-iFt LPS mAb in a PBS solution to a concentration of
1µg/mL. IC samples were then incubated overnight with shaking at 4oC. iFt and mAb-iFt
IC samples were then administrated intranasally (i.n.) following incubation.
2.4 Timeline for Immunization
In groups of three, C57BL/6 wild-type mice were immunized i.n. on day 0 and
followed up with a booster dosage on day 21. Inactivated LVS FT (iFt) was used to
immunize one group. The mAb-iFt immune complex (IC) was used to immunize another.
A control group of mice utilized PBS in place of the iFt and IC immunogens. Mice were
then challenged with a 1x104 CFU dosage of FT LVS on day 35. Following infection,
mice were sacrificed via CO2 overexposure on day 2 and day 5 as tissue collection of
spleen and lung samples occurred.
2.5 Dose Titrations of Wild-Type C57BL/6 Mice
Dose titrations were utilized to determine the lethal dose (LD100) for wild-type
mice. These mice were separated into 3 groups of mice with 5 mice in each group. F.
tularensis bacteria were administered intranasal (i.n.) with 5x103 CFU FT LVS, 1x104
CFU FT LVS, or 2x104 CFU FT LVS. Survival for both groups of mice was monitored
for 14 days post-infection. The dosage that eliminated about 100% of the experimental
group of mice by day 11 or 12 was utilized as the LD100 for immunization and challenge
studies.
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2.6 Flow Cytometry Screening
Samples of spleen and lung tissue were gathered pre-infection, on day 2 post
infection, and on day 5 post infection. For lung samples, an enzyme solution was required
to break down tissue. This digestion buffer contained RPMI (Life Technologies, 02.
mg/mL DNaseI (Sigma), 0.4 mg/mL Collagenase D (sigma), and 1 M MgCl2. A 30
minute incubation followed at 37oC before digested tissue samples were forced through a
cell strainer and the obtained suspension was washed and resuspended in RPMI
containing 2% FBS. Cell suspensions were then layered on 5 mLs of Lympholyte
(Cedarlane Laboratories- Burlington, NC), and spun for 30 minutes at RT. The resulting
interface containing immune cells was obtained from each sample and added to RPMI
with 2% FBS. 200,000 isolated immune cells from both spleen and digested lung samples
were stained for surface markers CD3 and CD4. Intracellularly, these immune cells were
stained for markers of IL17A and RORγT. Samples were stained with PerCp/Cy5.5 antiCD3 (BD Biosciences), FITC anti-CD4 (BD Biosciences), PE anti-IL17A (BD
Biosciences), and APC anti- RORγT (BD Biosciences).
2.7 Enzyme Linked Immunosorbent Assays (ELISAs)
The mice utilized in these experiments were separated into three groups with three
mice in each group. Samples of spleen and lung tissue were gathered on day 2 post
infection and on day 6 post infection. These samples were homogenized and spun down
by use of a centrifuge, and supernatant was collected and stored at -20oC. 96-well plates
were coated overnight with cytokine specific primary antibody according to vendor
instructions for each assay. Following the assay procedure, the 96-well plate was read
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using a SpectraMax M5 plate reader at wavelengths of 450 nm and 570 nm for
absorbance values to quantify attached proteins and background in each sample,
respectively. A standard of each cytokine was provided and serially diluted to establish a
curve to convert optical density to sample concentration. The assays employed consisted
of IL-23 (BD Biosciences), IL-12 (BD Biosciences), IL-17A (BD Biosciences), IL-6 (BD
Biosciences), and TGF-β1 (Invitrogen).
2.8 Statistical Analysis
The Log-Rank (Mantel-Cox) test was used for survival curves using the
GraphPad Prizm 4 software. The flow cytometry data was analyzed using the FlowJo
software.
2.9 Ethics Statement
All animals were handled in accordance with good animal practice defined by
relevant national and/or local animal welfare bodies. Briefly, mouse anesthesia was
performed via i.p. injections of a ketamine/xylazine cocktail, while mouse euthanasia was
achieved via CO2 administration followed by cervical dislocation.
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3. Results:
3.1 Identifying the LD100 Dose of FT LVS in C57BL/6 Mice
For the purpose of our study, it was necessary to determine a lethal dosage of FT
LVS in unimmunized wild-type C57BL/6 mice in order to define the lowest dose
required to eliminate about 100% of the experimental population in the absence of any
immunization protocol. The LD100 was identified as 1x104 CFU (colony forming units) of
F. tularensis live vaccine strain. The F. tularensis organisms were administered
intranasal.
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Figure 1: The Kaplan-Meier survival plot above illustrates dose titrations for C57BL/6
wild-type mice. Doses were titrated out to 2x104 CFU FT LVS, 1x104 CFU FT VLS, and
5x103 CFU FT LVS. A majority of the population had succumbed to infection by day 11
when faced with 1x104 CFU FT LVS challenge while a 5x103 CFU FT LVS dose still
showed complete survival on day 10. A 2x104 CFU FT LVS dosage eliminated its entire
population by day 10.
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3.2 Fcγ Receptor Targeting Mediates Protection against Lethal F. tularensis LVS
Challenge in C57BL/6 Mice
It has been previously demonstrated that intranasal administration of mAb-iFt ICs
enhance protection against FT LVS challenge (Rawool et al. 2008). Improved protection
is mediated by several cellular mechanisms using this Fc receptor-targeting model.
Binding of iFt to antigen presenting cells is heightened, and rate of iFt internalization by
APCs is increased (Iglesias et al. 2012). Mice were immunized on days 0 and 21 with
PBS, 1x109 iFt, or 1 µg/mL mAb-iFt and challenged on day 35 with 1x104 CFU FT LVS.
As a novel vaccination strategy, C57BL/6 wild-type mice were immunized with a
complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal antibody. These
mAb-iFt immunized mice showed complete protection from an otherwise lethal dosage
of FT LVS (1x104 CFUs). Unimmunized mice succumbed to the infection within 10-14
days. The use of mAb-iFt ICs demonstrates a straightforward approach for targeting
immunogens to FcR.
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Figure 2: Kaplan-Meier survival plot resulting from immunization and challenge
experiments of C57BL/6 wild-type mice. Wild-type C57BL/6 mice were immunized
before facing challenge with 1x104 CFU FT LVS. PBS mice represent the control group
with no immunization protocol. The iFt label represents mice immunized with F.
tularensis bacteria fixed with paraformaldehyde. The mAb-iFt label represents wild-type
mice immunized with a complex of inactivated F. tularensis and IgG2a, anti-LPS
monoclonal antibody. The results show that immunization of wild-type mice with mAbiFt exhibits complete protection.
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3.3 Fcγ Receptor Targeting Generates a Protective Th1 Response Against F. tularensis in
Immunized Mice
IL-12 down-regulation due to the unique F. tularensis LPS structure attributes to
the low endotoxic activity of the pathogen (Babadjanova et al. 2015). Pro-inflammatory
cytokines such as IL-12 and IL-17 offer vital protective roles against intracellular
infection. Recruitment, enhancement, and polarization of immune cells such as
neutrophils, macrophages, and T cell subsets are among the immunological benefits of
having these cytokines present. Importantly, IL-12 production facilitates the polarization
of Th1 cells, which are responsible for downstream IFN-γ production. In the focus of this
study, Th17 cells stimulate DCs and macrophages to produce IL-12 (Lin et al. 2012).
Evoking a Th1-cell response is critical in defense against this intracellular pathogen.
Even in mAb-iFt immunized mice, IFN-γ-/- mice have shown a significant drop in
survival rate in comparison to a wild-type control (Rawool et al. 2008). The efficiency of
a Th1 immune response is vital against intracellular bacteria. Here we aim to show that
Th1 responses are improved, inducted by IL-12 upregulation.
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IL-12 Cytokine Concentrations

Figure 3: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 6 post-infection time points. PBS mice represents the control group with no
immunization protocol. The iFt group represents mice immunized with F. tularensis
bacteria fixed with paraformaldehyde. The mAb-iFt label represents wild-type mice
immunized with a complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal
antibody. Figure shows IL-12 cytokine concentration in pg/mL, which contributes
towards a Th1 response. Both time points show IC immunized groups having a greater
concentration of this cytokine in lung and spleen samples. (*) P-value < 0.1; (**) P-value
< 0.05; bars represent SD.
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3.4 Recovery from F. tularensis Infection Relies on both Pro-inflammatory and Antiinflammatory Cytokines
Successful resolution of F. tularensis infection depends on the balance between
both pro-inflammatory and anti-inflammatory cytokines (Babadjanova et al. 2015). A
rapid pro-inflammatory response is expected in protected groups of mAb-iFt immunized
mice. Pro-inflammation is mediated by increased levels of cytokines such as IL-12 and
IL-6 (Fig. 3 and Fig. 6). Although increased levels of the anti-inflammatory cytokine IL10 have been reported to aid infectivity in unprotected groups (Babadjanova et al. 2015),
it is demonstrated here that protected groups show an increase in IL-10. This observation
suggests that a significant increase in the anti-inflammatory cytokine inhibits a harmful
extent of inflammation. The non-pathogenic subset of Th17 cells is known to produce IL10 in contrast to the cells found in inflammatory disease and autoimmune models
(Sharma et al. 2013). Furthermore, in IL10-/- mice, inflammation generated by IL-17 in
pulmonary infected mice leads to increased mortality following LVS infection (Slight et
al. 2013). Suppressive immune responses are essential to regulate potentially hazardous
pro-inflammation. Since protection is exhibited in mAb-iFt immunized subjects, proinflammatory responses have to be significantly reduced once the infection is resolved.
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IL-10 Cytokine Concentrations

Figure 4: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 5 post-infection time points. PBS mice represents the control group with no
immunization protocol. iFt represents mice immunized with F. tularensis bacteria fixed
with paraformaldehyde. The mAb-iFt label represents wild-type mice immunized with a
complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal antibody. Figure
shows IL-10 cytokine concentration in pg/mL. There is a significant increase of the
cytokine in both early post infection and day 5 post-infection time points among IC
immunized subjects across lung and spleen tissue samples. (*) P-value < 0.1; (**) Pvalue < 0.05; bars represent SD.
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3.5 Generation of Th17 Cells is TGF-β/IL-6 Dependent
Enhanced T cell activation is a mechanism by which mAb-iFt ICs improve the
immune response (Iglesias et al. 2012). Of the T cells induced, a subpopulation of T
helper cells, Th17 cells, is analyzed in this study. Th17 cells have an impact on the
dynamic of pro- and anti-inflammatory cytokine secretion throughout disease progression
and immune response (Slight et. al. 2013). IL-12 and IL-10 concentrations are effected by
Th17 cells, so it is of interest to determine the presence of polarizing cytokines of this T
helper subset. IL-23, IL-6, and TGF-β1 cytokines are involved in Th17 polarization and
effectiveness (Wu and Wang 2018). While IL-23 is more involved in maintenance and
expansion of Th17 cells, IL-6 and TGF-β are sufficient to direct naïve CD4 cells to a
Th17 lineage. Polarization via TGF-β1, opposed to TGF-β3, has a particular role in the
delicate balance of polarizing non-pathogenic Th17 cells over nonpathogenic Th17 cells
(Wu and Wang 2018).
Together with TGF-β, the IL-6 cytokine is critical for induction of transcription
factor RORγT, the key transcription factor that guides Th17 differentiation (Stadhousers
2017). This IL-6 cytokine is also pleiotropic, acting to inhibit Treg differentiation and has
a well-studied role in chronic inflammation (Tanaka et al. 2014). TGF-β1 and IL-6
concentrations are hypothesized to increase, demonstrating Th17 polarization. The
pleiotropic IL-6 is also expected to show a dramatic rise following the asymptomatic
early stages of infection in unprotected groups, signifying harmful over-inflammation.
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TGF-β1 Cytokine Concentrations

Figure 5: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 6 post-infection time points. PBS represents the control group of mice with no
immunization protocol. iFt represents mice immunized with F. tularensis bacteria fixed
with paraformaldehyde. The mAb-iFt label represents wild-type mice immunized with a
complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal antibody. It is
shown that TGF-β1 cytokine concentration is greater in lung samples from IC immunized
groups on both post infection time points. Spleen samples show a greater concentration in
IC groups on day 2, as iFt groups show similar concentrations on day 5. An early
response in both lung and spleen supernatant following pulmonary infection is reported.
(*) P-value < 0.1; (**) P-value < 0.05; bars represent SD.
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IL-6 Cytokine Concentrations

Figure 6: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 6 post-infection time points of IL-6. PBS represents the control group of mice with
no immunization protocol. iFt represents mice immunized with F. tularensis bacteria
fixed with paraformaldehyde. The mAb-iFt label represents wild-type mice immunized
with a complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal antibody.
The figure shows a large increase in concentration in between days 2 and 6 in PBS
control groups. There is little to no response in control and iFt immunized subjects 48
hours post-infection. As the infection progresses, however, a sharp increase in this proinflammatory IL-6 cytokine may correlate to its pathogenicity in PBS and iFt groups. (*)
P-value < 0.1; (**) P-value < 0.05; bars represent SD.
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3.7 Maintenance and Expansion of the Th17 Lineage via IL-23
Along with TGF-β1 and IL-6, the IL-23 cytokine is involved in the polarization
and expansion of Th17 cells. The extent to which IL-23 affects Th17 cell lineage is
unclear. Although incapable of solely polarizing naïve CD4 cells, IL-23 has an
indispensable role in promoting Th17 cell expansion and maintenance (Mus et. al. 2010).
IL-23 has also reported to be a key contributor to inducing and maintaining pathogenicity
in Th17 cells observed in inflammatory disease and autoimmune models (Lee 2015). Our
data shows that during the pulmonary infection utilized in this study, high levels of IL-23
concentration are reported in lung tissue of protected groups, but not in spleen tissue.
This result indicates that IL-23 cytokines appear early in response to pathogen at the site
of infection, but suggests these expansion and maintenance signals are not required in
spleen tissue when the infection becomes systemic.
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IL-23 Cytokine Concentrations

Figure 7: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 6 post-infection time points. The above figure shows IL-23 concentration, a cytokine
that expands the population of differentiated Th17 cells. PBS represents the control group
of mice with no immunization protocol. iFt represents mice immunized with F. tularensis
bacteria fixed with paraformaldehyde. The mAb-iFt label represents wild-type mice
immunized with a complex of inactivated F. tularensis and IgG2a, anti-LPS monoclonal
antibody. Cytokine concentration is greater in lung tissue samples from IC immunized
groups. In the lung, there is a significant increase in IL-23 cytokine concentration
observed in the mAb-iFt group. Relative to other cytokines measured, the concentration
of IL-23 is significantly lower in spleen tissue across all samples, never generating more
than 60 pg/mL opposed to roughly 300 pg/mL concentration seen in day 6 post-infection
IC lung tissue. (*) P-value < 0.1; (**) P-value < 0.05; bars represent SD.
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3.8 Confirming the Presence of Th17 Cells via Flow Cytometry
It is demonstrated here that targeting the iFt immunogen to Fcγ receptors
generates Th17 cells. ELISA data suggests that polarization occurs largely in the lung,
more noticeably in the earlier stages of infection. As the disease becomes systemic,
however, other immune organs are expected to become more engaged and flow
cytometry data suggests trafficking patterns of the cell population. Surface markers of the
CD3 and CD4 confirm cell lineage to be T helper cells. Intracellular markers for IL-17
and the transcription factor RORγT give a unique identity to lymphocytes as being Th17
lineage.
A significant increase of Th17 cells in mAb-iFt protected groups at 48 hours post
infection attributes to the importance of these cells early in pulmonary infection and their
contribution to the balance of pro- and anti-inflammatory response. The cytokine profiles
that result from the presence of Th17 cells influence the recruitment and activation of
other immune cells. Additionally, the increased presence of CD3+/CD4+ T cells is
indicative of increased internalization and presentation of antigen by APCs via the mAbiFt vaccination model. Early response also indicates that immunological memory is
generated following mAb-iFt immunization, allowing for recall response in subsequent
challenge.
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Day 2 Post Infection Lung Samples

Figure 8: The figure above shows flow cytometry data generated from digested lung
samples of mice treated with PBS, inactivated Francisella tularensis bacteria, and an
immune complex consisting of monoclonal antibody and inactivated Francisella
tularensis bacteria. The mice were challenged with 10K CFU FT LVS on day 35
following immunization on day 0 and a booster on day 21. The flow cytometry data
shown above represents day 2 post-infection. PBS control samples shows from roughly

39

200,000 isolated lymphocytes, 2.7% of positively selected T helper cells are Th17 cells.
iFt samples show 15.3% of positively selected T helper cells are Th17 cells. IC samples
showed 27.8% of positively selected T helper cells are Th17 cells. There was no
significant population of positively identified cells in pre-infection and day 6 post
infection samples (data not shown).
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Th17 Cells in Lung Post Infection

Figure 9: Positively identified Th17 cells from digested lung sample acquired at day 2
and day 5 post-infection of mice treated with PBS, inactivated Francisella tularensis
bacteria, and an immune complex consisting of monoclonal antibody and inactivated
Francisella tularensis bacteria. The mice were challenged with 10K CFU FT LVS on day
35 following immunization on day 0 and a booster on day 21. The number of positively
identified Th17 cells in IC immunized groups 48 hours post infection compared to the
control and iFt groups is roughly seven times and four times greater, respectively. Day 5
data showed the amount of Th17 cells in iFt and IC groups to be similar. (*) P-value <
0.1; (**) P-value < 0.05; bars represent SD.
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Pre-infection Spleen

Day 2 Post Infection Spleen
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Figure 10: The figure above shows flow cytometry data generated from spleen samples of
mice treated with PBS, inactivated Francisella tularensis bacteria, and an immune
complex consisting of monoclonal antibody and inactivated Francisella tularensis
bacteria. The mice were challenged with 10K CFU FT LVS on day 35 following
immunization on day 0 and a booster on day 21. Images A, B, and C in the figure show
pre-infection, day 2 post infection, and day 5 post infection lymphocytes, respectively.
Top down on each image shows respective groups based on immunization protocol. PBS
shows the control group with no inactivated pathogen present, the iFt data represents
groups immunized with only inactivated FT LVS while the IC group represents the group
immunized with immune complex of mAb-iFt. For pre-infection groups (A), PBS control
samples showed of roughly 200,000 isolated immune cells, 0.25% of positively identified
T helper cells are Th17 cells. iFt samples showed 0.358% of T helper immune cells to be
Th17 cells. IC samples showed 0.83% Th17 cells. For day 2 post infection (B), PBS
control samples 0.796% of positively identified T helper cells are Th17 cells. iFt samples
showed 0.877% of T helper cells are Th17 cells. For IC groups 1.46% of cells are Th17
cells. In day 5 post infection groups (C), PBS control samples showed 1.62% Th17 cells.
In iFt samples, 2.7% of T helper cells are found to be Th17 cells. In IC samples, the
number of positively identified Th17 cells had risen to 4.08%.
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Th17 Cells in Spleen Post Infection

Figure 11: Positively identified Th17 from isolated lymphocytes in spleen tissue samples
of mice treated with PBS, inactivated F. tularensis bacteria, and an immune complex
consisting of monoclonal antibody and inactivated F. tularensis bacteria. There is a minor
increase in Th17 cell population 48 hours post infection. By day 5 post-infection the
number of positively identified cells is roughly four fold greater in IC immunized
subjects in comparison to control and iFt immunization. The presence of a larger
population is suggestive of a memory recall response in mAb-iFt immunized subjects and
a beneficial role of identified cells. (*) P-value < 0.1; (**) P-value < 0.05; bars represent
SD.
The spleen sample result varies from what is observed in lung samples, where a
significant increase of positively identified Th17 cells is reported 48 hours post infection
before decreasing in day 5 samples. The route of infection in this experiment was
intranasal, and a prominent response in the lung is observed early as the pathogen likely
targets mucosal surfaces of the lungs and alveolar macrophages before becoming
systemic over time.
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3.9 IL-17A Secretion and Th17 Cell Response Contributes to the Generation of a
Protective Th1 Response
IL-17A (also referred to as IL-17) has strong pro-inflammatory characteristics and
is the primary effector cytokine of Th17 cells. IL-17A induces IL-12 production in
dendritic cells. The IL-17A cytokine also induces macrophage production of IL-12 and
IFN-γ, mediating critical Th1 responses (Lin et. al. 2009). IL-17A receptor is widely
expressed among non-hematopoietic cells. The functions of this receptor include
mediating the activation of transcription factor NF-κB via NF-κB activator 1 (Act1). The
cytoplasmic domain of IL-17RA is described as directly interacting with Act1 in order to
produce pro-inflammatory molecules. Additionally, treatment of fibroblasts and lung
epithelial cell samples with IL-17A has shown a prominent response of promoting
various immune responses such as granulopoeisis and neutrophil recruitment (Jin and
Dong 2013). An increased concentration of this cytokine in IC groups further indicates
the presence of Th17 cells and their role in protection against F. tularensis bacterial
infection.
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IL-17A Cytokine Concentrations

Figure 12: Data generated from ELISA analysis on lung and spleen samples at day 2 and
day 6 post-infection time points. Figure 12 shows concentration of IL17A protein. Day 6
post infection showed a significantly greater concentration of this cytokine in IC
immunized groups in lung and spleen samples. (*) P-value < 0.1; (**) P-value < 0.05;
bars represent SD.
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4. Discussion
Currently, there is no approved vaccine for Francisella tularensis bacterial
infection, the causative agent of tularemia (Rawool et al. 2008). F. tularensis is
considered by the Center for Disease Control to be a category A biological agent. Having
high risk for use as a bioweapon through ease of aerosol spread and low infectious dose
range, this pathogen poses as great a risk to public health as small pox and anthrax
(Sharma et al. 2011). It has been established that in a murine model, a mucosal
immunization protocol using an immune complex consisting of an inactivated form of F.
tularensis live vaccine strain (FT LVS) and an IgG2A, anti-LPS monoclonal antibody for
FcR targeting provides enhanced protection against FT LVS infection (Iglesias et al.
2012). The mechanism of FcγR-dependent uptake of antigen via APCs is expected here
to result in robust T cell activation. This combats mechanisms employed by the F.
tularensis pathogen such as MHC class II downregulation and an LPS component that
promotes anti-inflammatory response in early stages. Furthermore, the current study
investigates shifting the Th1/Th2 balance in favor of Th1 in mAb-iFt immunized samples
via polarizing cytokines. It is proposed that a particular subset of CD4+ T helper
lymphocytes, known as Th17 cells, have a protective role in host defense against this
intracellular bacterial pathogen using this novel vaccine strategy. The aim of the current
study is to demonstrate that protected subjects have an ability to generate an early Th17
response to combat the immune evasion strategy of F. tularensis bacteria.
In order to determine the presence of this lymphocyte population, flow cytometry
screening was utilized to determine unique surface and intracellular markers. A CD3
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surface marker was used to determine the lineage of lymphocytes as T cells. To classify
the cell population as T helper cells a CD4 surface marker was used. To define cells
distinctly as Th17 T helper cells, intracellular markers for IL-17 and RORγT transcription
factor were used. In order to generate a cytokine profile from inoculated and infected
tissue samples, enzyme linked immunosorbent assays for various cytokines were utilized.
It was first essential to determine a proper lethal dosage of FT LVS in
unimmunized wild type C57BL/6 mice. This dosage was identified as 1x104 CFU
administered i.n. (Figure 1). Once the dosage was defined, it was necessary to determine
the effectiveness of Fcγ receptor targeting immunization strategy. During a 16-day
observation period, the group of mAb-iFt immunized C57BL/6 mice exhibited a
complete 100% protection against an otherwise lethal 1x104 CFU dosage of FT LVS.
Control mice and mice immunized with a paraformaldehyde treated form of the bacteria
(iFt) showed mortality between days 10-14 (Figure 2).
Production of the IL-12 cytokine plays a significant role in overcoming the
molecular mechanism F. tularensis has on suppressing the Th1 response. Promoting a
Th1 response by inducing IL-12 ultimately results in production of IFN-γ, a beneficial
immune response against intracellular bacterial infection, such as F.tularensis. As F.
tularensis organisms infect host macrophages, IFN-γ limits intracellular replication. This
cytokine also leads to secretion of inflammatory cytokines and chemoattractants (Steiner
et. al. 2014). This current study demonstrates that in IC immunized groups, there is a
robust IL-12 response in both tissue samples across both time points (Fig. 3). Th17 cells
stimulate dendritic cells and macrophages to produce IL-12 (Lin et al. 2009). With IL-12
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secretion being secondhand, it is difficult to pinpoint this increase to Th17 cells alone.
However, it is evident that IL-12 production is largely beneficial to host immunity in
protected subjects throughout the course of infection.
The anti-inflammatory cytokine IL-10 rises significantly in protected groups at
later time points, suggesting that a potential over-inflammatory host response is being
curbed. For the early 48-hour post-infection time point in lung this may be true as well,
but there is no significant difference in spleen concentrations 48-hours post-infection.
These results could also indicate that the infection is becoming resolved at the later time
point, so greater suppression is necessary (Figure 4). Some IL-10 proteins are expected in
control mice as a mechanism of F. tularensis to inhibit IFN-γ production downstream
(Hunt et al. 2012). However, taken with the IL-17 data shown in figure 12, this IL-10
data may also suggest that more anti-inflammation signals are necessary when bacterial
clearance is occurring. There is also research that states the non-pathogenic subset of
Th17 cells secretes IL-10 opposed to the pathogenic subset that does not (Slight et al.
2013). Since the aim here is to characterize a protective role of Th17 cells, this IL-10
expression is an important distinction.
Polarization of Th17 cells from naïve T cells largely relies on signals from TGF-β
and IL-6. With the pneumonic route of infection used in this procedure, it was expected
that the largest population of protective cells would first appear in the lung. In agreement,
it is seen in figure 5 and figure 6 that the lung displays greater concentrations of these
cytokines at the earlier time point. This data suggests induction of Th17 cells from naïve
T cells is occurring in the lung before being trafficked to other areas of the body. The
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early response seen in these figures is also indicative of a recall response of quickly
generating Th17 cells in mAb-iFt immunized groups. In spleen samples, it is worth
noting that iFt immunized subjects show a dramatic increase in TGF-β1 concentration
between day 2 and day 5, possibly contributing to a limited ability to fend of the disease
in comparison to control subjects. Regardless, iFt groups show considerably less
protection than mAb-iFt immunized groups.
In addition to polarizing naïve T cells into Th17 cells, the pleiotropic IL-6
cytokine is known to be pro-inflammatory, and induces the differentiation of CD8+ T
cells into cytotoxic T cells (Tanaka et al. 2014). In both lung and spleen tissues, there is a
dramatic rise in concentration of IL-6 in PBS control groups between days 2 and 6 post
infection (Fig.6). Alternatively, IC immunized groups show a more gradual and
controlled rise in IL-6 concentration across these time points. Multiple aspects of IL-6
production are observed here. The controlled response in protected groups likely prevents
a cytokine storm from harming the host as opposed to control mice where a rapid and
robust concentration is reported day 6. Additionally, IL-6 polarizes Th17 cells in
conjunction with TGF-β, particularly at the early stage in lung tissue.
IL-23 cytokine concentrations from lung and spleen tissues samples are
represented in figure 7 at two post-infection time points of day 2 and day 6. IL-23 is a
cytokine responsible for expanding and maintaining Th17 cells post-differentiation (Mus
et. al. 2010). There is much more prevalent data generated from lung samples in this
instance, possibly due to the fact of this being a pneumonic infection. A noticeable
increase in the early time point of 48 hours post infection suggests a rapid immune
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response in protected mice. Expansion of Th17 cells in the lung in response to pulmonary
infection is expected. This increase can be correlated to Th17 cell expansion to combat
the anti-inflammatory properties of FT LVS pulmonary infection and promote effective
clearance of the bacteria. This sudden polarization of Th17 cells in protected mice further
illustrates the memory recall response of the mAb-iFt vaccine model. This also
demonstrates that Th17 cell expansion is likely occurring in the lung rather than the
spleen. As the concentration of IL-23 continues to rise in day 6 lung samples, the protein
concentrations roughly remain level in iFt-immunized samples. IL-23 is described by
Sharma et al. to be a contributor to the pathogenicity of Th17 cells, but here a clear
increase in IL-23 is seen in protected groups. This data agrees more closely with research
of Lin et al. (2009), who described the IL-23-Th17 cell pathway as critical for optimal
induction of Th1 cell responses and protection against F. tularensis LVS. This group also
determined that lung CFU was greater in IL-23-/- mice, and IL-17 production decreased in
comparison to wild-type C57BL/6 mice following pulmonary FT LVS infection (Lin et.
al. 2009).
In the earlier time point of 48-hours post intranasal infection there is a significant
upregulation of positively identified Th17 cells in lung. Positively identified Th17 cells in
isolated lymphocyte samples from digested lung tissue as shown by cell populations in
figure 8 and figure 9. Being a pneumonic infection administered via intranasal, the lung is
the likely early site of interaction between pathogen and host immune cells. As the
infection progresses into day 6, the population of Th17 cells tapers off in lung,
presumably as the host pulmonary tissue tries to regain normalcy and not prolong the
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associated inflammation. This also exemplifies the trafficking of Th17 cells from the lung
to other immune organs.
Inoculation and infection route plays a significant role in cellular response.
Generally, the most virulent form of tularemia infection is inhalation resulting in a
pneumonic infection with up to a 60% mortality rate (Roberts et al. 2018). It is likely that
the robust 48-hour response in the lung is critical to the survival of our protected groups.
Control PBS groups exemplify the asymptomatic inoculation of the disease as a relatively
low number of Th17 cells that are recruited (Fig. 8 and Fig. 9).
The trafficking of Th17 cells is observed as the population of positively identified
Th17 cells in spleen tissue rises almost simultaneously with the population decreasing in
lung tissue. The presence of positively identified cells rises nearly four times in spleen
tissue of IC immunized groups from pre-infection samples to day 5 post infection isolated
lymphocyte samples (Fig. 10 and Fig. 11). The significantly larger number of Th17 cells
day 5 post-infection suggests progression of the disease as the pulmonary infection
spreads to other areas of the host.
The primary effector cytokine released by Th17 cells is known to be IL-17.
ELISA data analysis reveals that the concentration of this cytokine is prevalent at the
later time point post-infection in protected groups (Fig. 8). The delayed response could be
in part due to IL-17A’s role as a metaphorical clean-up crew, giving one last
inflammatory push and signaling to phagocytes. IL-17A is a powerful pro-inflammatory
mediator and recruiter of innate immune cells such as neutrophils in response to
intracellular bacterial infection (Jin and Dong 2013). IL-17A and the IL-17 family of
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cytokines as a whole are also linked as a driving force in chronic inflammation, which
leads to tissue damage and autoimmune diseases such as rheumatoid arthritis and
multiple sclerosis (Jin and Dong 2013). Perhaps the delayed response is the immune
system pacing lightly as not to evoke an overly pro-inflammatory response in the host.
It is a concerted cellular effort to rid the host of tularemia infection. Th17 cells, as
well as other T cell subsets, NK cells, and several other cell types coordinate a protective
immune response against the bacterial pathogen. Although other cell types are involved
in the immune response, it was our goal here to determine that Th17 cells do in fact hold
a protective role. The early recall response seen in the lung and the associated cytokine
profiles (Fig. 3, 5, 6, and 7, notably) possibly indicate the presence of a memory pool of
Th17 cells induced by immunizations that occur on day 0 and day 21 before the day 35
infection. Additional study on this topic would include analyzing this potential memory
pool of cells for distinctive surface marker separate of the Th17 cells observed in control
groups. Furthermore, the use of IL-17-/- knockout mouse models could be an area of
future study. Early post infection cytokine concentrations appear low for this effector
cytokine, so it would be of interest to observe how host immunity is affected at this early
stage. IL-17 is a potent promoter of neutrophil expansion and recruitment (Gaffen 2008).
IL-17 induces IL-12 production in dendritic cells and promotes IL-12 and IFN-γ
production in macrophages, mediating critical Th1 responses (Lin e. al. 2009).
Additionally, IL-17 acts on various anti-microbial genes via a number of signaling
pathways to upregulate molecules such as β-defensins, calgranulins and mucins (Gaffen
2008). As previously mentioned, the cytoplasmic domain of IL-17RA directly interacts
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with Act1 in order to produce pro-inflammatory molecules through NF-κB activation as
well (Jin 2013).
Alternatively, another gene target of IL-17 is CCL20, a chemokine with a known
role in Rheumatoid arthritis pathology via activation of the MEK NF-κB signaling
pathway. Even in infection, IL-17 can hold a detrimental role to host. In the case of
Candida albicans infection in mice, alleviating the IL-17 response with IL-17 antibody
treatment lightens pathogenic inflammation (Gaffen 2008). Therefore, aside from
generating pro-inflammatory signals, a complete list of signaling targets for the IL-17
cytokine is far from being completed. Aside from observing pro-inflammatory cytokine
concentrations, these proposed future experiments involving IL-17-/- knockout mice
would include dose titration studies to analyze the extent of protection that IL-17
provides in F. tularensis infection.
In terms of advancing the vaccination model utilized in this experiment, the FcγR
targeting method should be further investigated. The proposed mechanism of FcγRdependent uptake of antigen via APCs results in robust T cell activation. This contests
immune evasion tools employed by the F. tularensis pathogen such as MHC class II
downregulation and an LPS component that promotes anti-inflammatory response in
early stages. Furthermore, this mAb-iFt strategy shows success in combating intracellular
bacteria by shifting the Th1/Th2 balance in favor of Th1 in mAb-iFt immunized samples
via polarizing cytokines. Additional studies may benefit from using the more virulent
type A F. tularensis SchuS4 strain. It is reported that protective mechanisms imposed by
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IL-17 do not afford the same protection in the more virulent strain (Skyberg 2013). The
FcγR targeting method should be further investigated in these studies.
A different approach to further understanding the mechanisms of Th17 cells could
also be to utilize models displaying autoimmune or chronic inflammatory diseases.
Isolation of lymphocytes from rheumatoid arthritis or multiple sclerosis murine models
could be compared and contrasted to the T helper subpopulation seen in this study. Th17
cells are described as being subdivided into having pathogenic and nonpathogenic
subsets, and this dynamic should be of interest moving forward. It has been shown in this
study that protection to lethal F. tularensis infection is conferred by an FcγR-targeting
vaccination strategy. In protected subjects, there is rapid growth in a population of
positively identified Th17 cells following an otherwise lethal challenge. It is clear that in
this intracellular bacteria challenge, Th17 cells offer a protective role.
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